Orange Book product · Brand (NDA)
VITEKTA
ELVITEGRAVIR
At a glance
Sep 24, 2014
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 24, 2014
11 yr 11 mo ago
Today
Patent 7176220 expires
Listed drug substance patent expiration.
Aug 27, 2026
in 2 mo
Patent 7635704 expires
Listed drug substance patent expiration.
Oct 26, 2026
in 4 mo
Patent 8981103 expires
Listed drug substance patent expiration.
Oct 26, 2026
in 4 mo
Patent 7176220*PED expires
Listed listed patent expiration.
Feb 27, 2027
in 8 mo
Patent 7635704*PED expires
Listed listed patent expiration.
Apr 26, 2027
in 10 mo
Patent 8981103*PED expires
Listed listed patent expiration.
Apr 26, 2027
in 10 mo
Pharmaceutical detail
Active ingredient
ELVITEGRAVIR
Strength
85MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 203093
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7176220 | Aug 27, 2026 | in 2 mo | SubstanceProductU-257 |
| 7635704 | Oct 26, 2026 | in 4 mo | SubstanceProductU-257 |
| 8981103 | Oct 26, 2026 | in 4 mo | SubstanceProduct |
| 7176220*PED | Feb 27, 2027 | in 8 mo | |
| 7635704*PED | Apr 26, 2027 | in 10 mo | |
| 8981103*PED | Apr 26, 2027 | in 10 mo |
